Genprex Inc., a clinical-stage gene therapy company, has announced positive preliminary preclinical data for its diabetes gene therapy candidate, GPX-002. The results, which have already been released, show in vivo proof-of-concept in both non-human primate and mouse models of Type 2 diabetes. In these studies, GPX-002 was able to rejuvenate exhausted beta cells and normalize glucose levels. The therapy uses an adeno-associated virus vector to deliver genes directly into the pancreas, either via the pancreatic duct or by direct injection. These promising results mark a significant step toward advancing GPX-002 into human clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA56645) on January 06, 2026, and is solely responsible for the information contained therein.